Story · Medicine & Biotech · Mind & Brain

Celecoxib in Reducing Cognitive Impairment with Neoadjuvant Chemotherapy or Definitive Chemoradiation for Head and Neck Carcinoma (CELCI-HN): A Phase II Randomized Trial

1 outlet · first reported by Research Square 9h ago

Coverage, in order

  1. 9h ago
    Research Square obscure study randomized trial
    Celecoxib in Reducing Cognitive Impairment with Neoadjuvant Chemotherapy or Definitive Chemoradiation for Head and Neck Carcinoma (CELCI-HN): A Phase II Randomized Trial

    Purpose Chemotherapy-related cognitive impairment (CRCI) is an under-recognized consequence of cancer therapy, particularly in head and neck squamous cell carcinoma (HNSCC) patients receiving neoadjuvant chemotherapy (NACT) or definitive chemoradiation (CTRT). Celecoxib, a selective…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.